A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
151actual
Sites
47
Countries
Canada, Japan, South Korea +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-02 | actual | When the study began enrolling |
| Primary completion | 2025-04-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-16 | actual | The whole study's end, after follow-up |
| First posted | 2024-01-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Combination product: Rocatinlimab Prefilled Syringe — also filed as AMG 451
- Combination product: Rocatinlimab AI — also filed as AMG 451
Primary outcome
what the primary-completion date above is the date OFProportion of Full-dose Self-administered Rocatinlimab Injections Among Total Attempted Injections up to Week 16
measured Up to Week 16
Publications
- PMID 40012373 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed